Impact of Chronic Treatment by β1-adrenergic Antagonists on Nociceptive-Level (NOL) Index Variation After a Standardized Noxious Stimulus Under General Anesthesia

NCT ID: NCT04060095

Last Updated: 2020-09-02

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 33 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-08-27
• Study Completion Date: 2020-03-04

Brief Summary

The aim of the present study is to investigate the effect of chronic treatment with β1-adrenergic antagonist on the NOL index variation, the heart rate variation and the mean blood pressure variation after a standardized noxious stimulus.

Detailed Description

Hypothesis: We hypothesize that the NOL values variations obtained in response to a standardized noxious stimulus under general anesthesia in a group of patients chronically treated with β1-adrenergic antagonists, will be similar to the NOL values variations previously obtained in response to a similar standardized noxious stimulus and previously reported in a group of patients without any β1-adrenergic antagonist.

Background: The Pain Monitoring Device (PMD200TM) monitor (Medasense Biometrics Ltd., Ramat Gan, Israel) uses the Nociception Level (NOL) index, a multiple parameter-derived index that has recently shown a good sensitivity and specificity to detect noxious stimuli. The NOL index variations of the latest version of the PMD200TM has shown better sensitivity and specificity to detect standardized noxious stimulus than heart rate or blood pressure variation in a population without any β1-adrenergic antagonist treatment. β1-adrenergic antagonist treatment was so far a limitation to the use of the NOL index. Indeed, β1-adrenergic antagonists have a depressive action on the heart rate, including limitation of the heart rate variability after a noxious stimulus. Because heart rate and its variability are parameters which are part of the parameters combined to build the NOL index, chronic treatment with β1-adrenergic antagonist could alter the ability of the NOL index to detect noxious stimulus. However, Edry R. (Edry R, 2017) assessed the impact of chronic treatment with β1-adrenergic antagonist on NOL index variation after noxious stimuli in a pilot study (9 patients under chronic treatment with β1-adrenergic antagonist and under general anesthesia) and didn't show any influence of this treatment on the NOL index variation. But this study was not large enough and did not fully answered the question whether chronic treatment with β1-adrenergic antagonist might impact NOL ability to detect precise and standardized stimulus and to compare the results to those in patients without this type of chronic medication.

Objectives:

Primary objective:

To explore the NOL variation in a group of patients under chronic treatment with β1-adrenergic antagonists submitted to standardized noxious stimulus under general anesthesia.

Secondary objectives:

Secondary outcome [1] To explore the heart rate variation and the mean blood pressure variation in a group of patients under chronic treatment with β1-adrenergic antagonists submitted to standardized noxious stimulus under general anesthesia.

Secondary outcome [2] To compare the heart rate variation and the mean blood pressure variation in a group of patients under chronic treatment with β1-adrenergic antagonists submitted to standardized noxious stimulus under general anesthesia to a control group of patients without any β1-adrenergic antagonist chronic treatment; results gathered from a previous study (Renaud-Roy E, 2019), exposed to the same noxious stimulus and under the same anesthesia conditions.

Secondary outcome [3] To explore the ability of the NOL index, the heart rate and the mean blood pressure to discriminate between noxious and non-noxious states in a group of patients with β1-adrenergic antagonist chronic treatment submitted to standardized noxious stimulus under general anesthesia. To determine sensitivity and specificity (ROC curve and AUC of ROC) for each parameter: HR, MAP, NOL index.

Secondary outcome [4] To evaluate the NOL index, the heart rate and the mean blood pressure variations after tracheal intubation in patients with β1-adrenergic antagonist chronic treatment.

Methods:

Adult patients undergoing general anesthesia for any types of surgery and who have been chronically treated with β1-adrenergic antagonists for at least three months prior to surgery will be enrolled to reach a total of patients with full analysis of data of n=25. All patients will be consented prior to the surgery. Induction of anesthesia will be standardized for all patients and based on their adjusted body weight calculated before induction, with: IV midazolam (0.02mg/kg), IV propofol (1.5-2mg.kg-1), IV remifentanil (1mcg.kg-1 followed by a continuous infusion of 0.05 µg.kg-1.min-1), IV rocuronium (0.6 to 1mg.kg-1). Depth of anesthesia with desflurane will be maintained and monitored with the BIS index kept between 40 and 60. Intubation will be performed 3 minutes after the intravenous administration of the propofol, remifentanil and rocuronium boluses. The end of the bolus of remifentanil (given 1mcg/kg; adjusted body weight) will be the start of the 3 min period to wait before proceeding with the tracheal intubation. Three minutes after intubation, the remifentanil infusion will be decreased to 0.005 µg.kg-1.min-1 to reduce the risk of developing hypotensive events and to prepare the patient for the standardized noxious stimulus of the study protocol realized under very low doses of opioids under desflurane hypnosis with BIS 40-60.

At least 10 min after the post-intubation decrease of the remifentanil infusion rate, the OR team will stop any physical contact/stimulation of the patient allowing at least a 3-minutes rest period under stable anesthesia. Baseline mean arterial blood pressure (MAP) and heart rate (HR) will be defined for the rest of the study as the mean of 3 measures in the 3 minutes during this "no pain - no touching" evaluation period to get baselines values of all the study parameters. If necessary, phenylephrine will be given to keep a MAP > 65 mmHg.

At this point, the standardized electrical (tetanic) stimulation will be applied on the area of the ulnar nerve at the wrist level, at a frequency of 100 Hz and a current of 70 mA for a duration of 30 seconds, followed by 3 minutes of observation period without any other stimulation of the patient by the anesthesia or the surgical team (EZstimII, Model ES400, Life-Tech, Stafford, Tx, USA). At the end of the observation period, the study is discontinued and the anesthesia will be conducted at the discretion of the anesthesiologist in charge of the patient.

Conditions

Nociception During Anesthesia in Patients Taking β1-adrenergic Antagonist Chronic Treatment

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

β1-adrenergic antagonists

Patients who have been treated for more than 3 months with β1-adrenergic antagonists

standardized noxious stimulus under general anesthesia.

Intervention Type: PROCEDURE

50 adult patients undergoing general anesthesia for any types of surgery and who have been chronically treated with β1-adrenergic antagonists for at least three months. .Induction of anesthesia will be standardized.

At least 10 min after the post-intubation decrease of the remifentanil infusion rate, the OR team will stop any physical contact/stimulation of the patient allowing at least 3-minutes.

At this point, the standardized electrical (tetanic) stimulation will be applied on the area of the ulnar nerve at the wrist level, at a frequency of 100 Hz and a current of 70 mA for a duration of 30 seconds, followed by 3 minutes of observation period without any other stimulation of the patient by the anesthesia or the surgical team. At the end of the observation period, the study is discontinued and the anesthesia will be conducted at the discretion of the anesthesiologist in charge of the patient.

Interventions

standardized noxious stimulus under general anesthesia.

50 adult patients undergoing general anesthesia for any types of surgery and who have been chronically treated with β1-adrenergic antagonists for at least three months. .Induction of anesthesia will be standardized.

At least 10 min after the post-intubation decrease of the remifentanil infusion rate, the OR team will stop any physical contact/stimulation of the patient allowing at least 3-minutes.

At this point, the standardized electrical (tetanic) stimulation will be applied on the area of the ulnar nerve at the wrist level, at a frequency of 100 Hz and a current of 70 mA for a duration of 30 seconds, followed by 3 minutes of observation period without any other stimulation of the patient by the anesthesia or the surgical team. At the end of the observation period, the study is discontinued and the anesthesia will be conducted at the discretion of the anesthesiologist in charge of the patient.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

1. Patient age > 18 years

2. ASA I-III

3. Adult patients scheduled to undergo elective surgery under general anesthesia

4. Patients chronically treated with β1-adrenergic antagonists for at least three months prior to surgery

5. Patient able to consent in the language of the including center

Exclusion Criteria

1. Use of any type of anesthesia (neuraxial, epidural or local regional anesthesia) without general anesthesia

2. Patients with non-regular sinus cardiac rhythm, implanted pacemakers, prescribed antimuscarinic agents, α2-adrenergic agonists, and antiarrhythmic agents others than β1-adrenergic antagonists

3. Emergent surgery

4. Pregnancy/lactation. Pregnancy test will be performed in all women of child bearing age

5. BMI > 40 kg/m2

6. Preoperative hemodynamic disturbance

7. Central nervous system disorder (neurologic/head trauma/uncontrolled epileptic seizures)

8. Peripheric nervous system disorder (troubles of the peripheric nervous conduction, diabetic neuropathy)

9. Pre-operative chronic opioid use or chronic pain, equivalent to oxycodone 20mg per oral, per day for more than 6 weeks

10. Chronic use of psychoactive drugs within 90 days prior to surgery

11. Medical conditions qualifying for ASA III or IV:

1. Untreated or persistent peripheral or central cardiovascular disease

2. Severe pulmonary disease e.g. COPD gold 4, FEV< 1.0l/s, or (evidence of) elevated paCO2 > 6.0 kPa

3. Significant hepatic disease with increased bilirubin, INR or low albumin

4. History of severe cardiac arrhythmia eg. Chronic atrial fibrillation.

5. Active pacemaker or defibrillator

12. Allergy or intolerance to any of the study drugs

13. Cardiac arrhythmia during the period of the study

14. Unexpected difficult airway requesting excessive, possibly painful airway manipulations

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Ciusss de L'Est de l'Île de Montréal

OTHER

Sponsor Role: lead

Responsible Party

Philippe Richebe

Professor Anesthesiology and Pain Medicine

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Philippe PR Richebé, MD PhD

Role: PRINCIPAL_INVESTIGATOR

CIUSSS Est de l'ile de Montreal

Locations

Hopital Maisonneuve Rosemont, CIUSSS de l'Est de l'Ile de Montreal

Montreal East, Quebec, Canada

Countries

Canada

Other Identifiers

2020-1946

Identifier Type: -

Identifier Source: org_study_id